Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.31 |
| ▸ | TUBB | P07437 | 1/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983540 | 0.87 | VCAM1 (0.36) | VCAM1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL5983680 | 0.86 | VCAM1 (0.35) | VCAM1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL5984262 | 0.85 | VCAM1 (0.33) | VCAM1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL5984287 | 0.85 | VCAM1 (0.39) | VCAM1ALDH1A1KMT2AVCP | |
| SCHEMBL5984007 | 0.83 | VCAM1 (0.34) | VCAM1ALDH1A1TSHRTDP1KMT2A | |
| SCHEMBL5984722 | 0.82 | VCAM1 (0.41) | VCAM1 | |
| SCHEMBL5985457 | 0.81 | — | — | |
| SCHEMBL6731121 | 0.81 | ALOX5 (0.34) | VCAM1L3MBTL1 | |
| SCHEMBL5984127 | 0.80 | VCAM1 (0.45) | VCAM1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5984640 | 0.80 | VCAM1 (0.32) | VCAM1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | claimed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | claimed |
| EP-1077694-B1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | RENOVIS INC (US) | 2004-07-21 | — | — | EP | claimed |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | claimed |
| US-6998419-B2 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | RENOVIS, INC. | 2005-09-29 | — | — | US | disclosed |
| US-6835754-B2 | Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example | RENOVIS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-10-07 | — | — | US | disclosed |
| EP-1077694-B1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | RENOVIS INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6730700-B2 | 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | RENOVIS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6342523-B1 | DRUGS AND ANTIINFLAMMATORY AGENTS | CENTAUR PHARMACEUTICALS, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1135367-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Centaur Pharmaceuticals, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6258852-B1 | NITRONE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1077694-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6083989-A | ADMINISTERING TO THE PATIENT SUFFERING FROM INFLAMMATORY BOWL MOVEMENT AN N-SUBSTITUTED ARYL NITRON COMPOUND OR SALT | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-2000032567-A1 | 3,4,5-TRISUBSTITUTED ARYL NITRONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999059576-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | VCAM1 3354/4885ALDH1A1 219/4885TSHR 2366/4885 |
| US-20030078297-A1 | 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | VCAM1 316/4885ALDH1A1 121/4885TSHR 1520/4885 |
| US-20040198835-A1 | 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same | NOS1, NOS3, CBR1 | VCAM1 258/4885ALDH1A1 114/4885TSHR 1875/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | VCAM1 3588/4885ALDH1A1 200/4885TSHR 3060/4885 |
| US-20050215646-A1 | Methods for treating multiple sclerosis and pharmaceutical compositions therefor | CCL11, TXNRD3, CX3CR1 | VCAM1 198/4885ALDH1A1 1148/4885TSHR 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.